Marcin Kowanetz Selected Research

atezolizumab

1/2021	C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.
1/2021	Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade.
11/2020	Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.
1/2020	Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer.
12/2019	Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
1/2019	Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
1/2019	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
1/2019	Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab.
11/2018	FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.
10/2018	Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marcin Kowanetz Research Topics

Disease

27	Neoplasms (Cancer) 01/2021 - 09/2006
15	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 04/2016
6	Neoplasm Metastasis (Metastasis) 01/2019 - 04/2010
2	Disease Progression 01/2021 - 01/2018
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2021
1	Renal Cell Carcinoma (Grawitz Tumor) 11/2020
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020
1	Neutropenia 01/2019
1	Brain Neoplasms (Brain Tumor) 11/2018
1	Autoimmune Diseases (Autoimmune Disease) 01/2017
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2017
1	Fibrosis (Cirrhosis) 06/2013
1	Sarcoma (Soft Tissue Sarcoma) 05/2013
1	Melanoma (Melanoma, Malignant) 05/2013
1	Pancreatic Neoplasms (Pancreatic Cancer) 04/2013
1	Adenocarcinoma 04/2013
1	Hematologic Neoplasms (Hematological Malignancy) 03/2013
1	Multiple Myeloma 03/2013
1	Multiple Endocrine Neoplasia Type 1 01/2008
1	Pituitary Neoplasms (Pituitary Adenoma) 01/2008
1	Rheumatoid Arthritis 09/2006
1	Macular Degeneration (Age-Related Maculopathy) 09/2006

Drug/Important Bio-Agent (IBA)

19	atezolizumabIBA 01/2021 - 11/2014
7	B7-H1 AntigenIBA 01/2020 - 11/2014
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2018 - 09/2006
5	Proteins (Proteins, Gene)FDA Link 01/2021 - 04/2009
4	AntibodiesIBA 01/2021 - 04/2010
4	Monoclonal AntibodiesIBA 01/2019 - 01/2008
3	LigandsIBA 01/2021 - 08/2017
3	Docetaxel (Taxotere)FDA Link 01/2018 - 04/2016
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 04/2013 - 04/2009
2	AntigensIBA 01/2021 - 12/2019
2	Blocking AntibodiesIBA 11/2020 - 04/2010
2	Biomarkers (Surrogate Marker)IBA 12/2019 - 01/2019
2	Carboplatin (JM8)FDA LinkGeneric 01/2019 - 01/2019
2	Bevacizumab (Avastin)FDA Link 01/2019 - 06/2018
2	PlatinumIBA 01/2019 - 01/2017
2	Placenta Growth FactorIBA 04/2010 - 04/2009
1	cyclopropapyrroloindoleIBA 01/2021
1	human ERBB2 proteinIBA 01/2021
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2021
1	C-Reactive ProteinIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 12/2019
1	Peptides (Polypeptides)IBA 12/2019
1	EpitopesIBA 12/2019
1	Immune Checkpoint InhibitorsIBA 01/2019
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2019
1	CateninsIBA 01/2019
1	Tyrosine Kinase InhibitorsIBA 01/2019
1	130-nm albumin-bound paclitaxelIBA 01/2019
1	Coloring Agents (Dyes)IBA 01/2019
1	ChemokinesIBA 01/2019
1	2,3,6-trichloroindophenolIBA 01/2019
1	Biological ProductsIBA 10/2018
1	1-methyl-1-piperidinomethane sulfonateIBA 01/2018
1	Transforming Growth Factors (Transforming Growth Factor)IBA 06/2013
1	Platelet-Derived Growth FactorIBA 06/2013
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 06/2013
1	VemurafenibIBA 05/2013
1	p21-Activated KinasesIBA 05/2013
1	Therapeutic UsesIBA 05/2013
1	PF 3758309IBA 05/2013
1	Mitogen-Activated Protein KinasesIBA 05/2013
1	dabrafenibIBA 05/2013
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 04/2013
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 03/2013
1	2- (1H- indazol- 4- yl)- 6- (4- methanesulfonylpiperazin- 1- ylmethyl)- 4- morpholin- 4- ylthieno(3,2- d)pyrimidineIBA 03/2013
1	Pharmaceutical PreparationsIBA 08/2012
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 08/2012
1	Sunitinib (Sutent)FDA Link 08/2012
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 04/2010
1	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 04/2010
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 04/2009
1	CytokinesIBA 04/2009
1	ProlactinIBA 01/2008

Therapy/Procedure

8	Immunotherapy 01/2021 - 06/2015
7	Therapeutics 12/2019 - 04/2009
6	Drug Therapy (Chemotherapy) 01/2019 - 01/2017
1	Adjuvant Chemotherapy 11/2018
1	Transplantation 12/2010